These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
294 related articles for article (PubMed ID: 21740480)
1. Differences in Kaposi sarcoma-associated herpesvirus-specific and herpesvirus-non-specific immune responses in classic Kaposi sarcoma cases and matched controls in Sicily. Amodio E; Goedert JJ; Barozzi P; Riva G; Firenze A; Bonura F; Viviano E; Romano N; Luppi M Cancer Sci; 2011 Oct; 102(10):1769-73. PubMed ID: 21740480 [TBL] [Abstract][Full Text] [Related]
2. Seroreactivity to Kaposi's sarcoma-associated herpesvirus (human herpesvirus 8) latent nuclear antigen in AIDS-associated Kaposi's sarcoma patients depends on CD4+ T-cell count. de Souza VA; Pierrotti LC; Sumita LM; Freire WS; Segurado AA; Pannuti CS J Med Virol; 2007 Oct; 79(10):1562-8. PubMed ID: 17705173 [TBL] [Abstract][Full Text] [Related]
3. Trends in Kaposi's sarcoma-associated Herpesvirus antibodies prior to the development of HIV-associated Kaposi's sarcoma: a nested case-control study. Wakeham K; Johnston WT; Nalwoga A; Webb EL; Mayanja BN; Miley W; Elliott AM; Whitby D; Newton R Int J Cancer; 2015 Jun; 136(12):2822-30. PubMed ID: 25395177 [TBL] [Abstract][Full Text] [Related]
4. Comparison of human sera reactivities in immunoblots with recombinant human herpesvirus (HHV)-8 proteins associated with the latent (ORF73) and lytic (ORFs 65, K8.1A, and K8.1B) replicative cycles and in immunofluorescence assays with HHV-8-infected BCBL-1 cells. Zhu L; Wang R; Sweat A; Goldstein E; Horvat R; Chandran B Virology; 1999 Apr; 256(2):381-92. PubMed ID: 10191203 [TBL] [Abstract][Full Text] [Related]
5. Low T cell responses to human herpesvirus 8 in patients with AIDS-related and classic Kaposi sarcoma. Guihot A; Dupin N; Marcelin AG; Gorin I; Bedin AS; Bossi P; Galicier L; Oksenhendler E; Autran B; Carcelain G J Infect Dis; 2006 Oct; 194(8):1078-88. PubMed ID: 16991082 [TBL] [Abstract][Full Text] [Related]
6. A prospective study of Kaposi's sarcoma-associated herpesvirus and Epstein-Barr virus in adults with human immunodeficiency virus-1. Newton R; Carpenter L; Casabonne D; Beral V; Babiker A; Darbyshire J; Weller I; Weiss R; Kwan A; Bourboulia D; Munoz F; Lagos D; Boshoff C Br J Cancer; 2006 May; 94(10):1504-9. PubMed ID: 16705315 [TBL] [Abstract][Full Text] [Related]
7. Kaposi Sarcoma Herpesvirus (KSHV) Latency-Associated Nuclear Antigen (LANA) recruits components of the MRN (Mre11-Rad50-NBS1) repair complex to modulate an innate immune signaling pathway and viral latency. Mariggiò G; Koch S; Zhang G; Weidner-Glunde M; Rückert J; Kati S; Santag S; Schulz TF PLoS Pathog; 2017 Apr; 13(4):e1006335. PubMed ID: 28430817 [TBL] [Abstract][Full Text] [Related]
8. Impact of Kaposi sarcoma-associated herpesvirus (KSHV) burden and HIV coinfection on the detection of T cell responses to KSHV ORF73 and ORF65 proteins. Woodberry T; Suscovich TJ; Henry LM; Martin JN; Dollard S; O'Connor PG; Davis JK; Osmond D; Lee TH; Kedes DH; Khatri A; Lee J; Walker BD; Scadden DT; Brander C J Infect Dis; 2005 Aug; 192(4):622-9. PubMed ID: 16028131 [TBL] [Abstract][Full Text] [Related]
9. Delayed-type hypersensitivity in classic Kaposi sarcoma patients and controls. Valenti RM; Amodio E; Nam JM; Preiss L; Graubard BI; Romano N; Goedert JJ Br J Cancer; 2011 Feb; 104(3):433-6. PubMed ID: 21245864 [TBL] [Abstract][Full Text] [Related]
10. Prevalence of Kaposi's sarcoma associated herpesvirus infection measured by antibodies to recombinant capsid protein and latent immunofluorescence antigen. Simpson GR; Schulz TF; Whitby D; Cook PM; Boshoff C; Rainbow L; Howard MR; Gao SJ; Bohenzky RA; Simmonds P; Lee C; de Ruiter A; Hatzakis A; Tedder RS; Weller IV; Weiss RA; Moore PS Lancet; 1996 Oct; 348(9035):1133-8. PubMed ID: 8888167 [TBL] [Abstract][Full Text] [Related]
12. Kaposi sarcoma-associated herpesvirus, HIV-1 and Kaposi sarcoma risk in black South Africans diagnosed with cancer during antiretroviral treatment rollout. Motlhale M; Muchengeti M; Bradshaw D; Chen WC; Singini MG; de Villiers CB; Lewis CM; Bender N; Mathew CG; Newton R; Waterboer T; Singh E; Sitas F Int J Cancer; 2023 May; 152(10):2081-2089. PubMed ID: 36727526 [TBL] [Abstract][Full Text] [Related]
13. Detection of antibodies to Kaposi's sarcoma-associated herpesvirus: a new approach using K8.1 ELISA and a newly developed recombinant LANA ELISA. Mbisa GL; Miley W; Gamache CJ; Gillette WK; Esposito D; Hopkins R; Busch MP; Schreiber GB; Little RF; Yarchoan R; Ortiz-Conde BA; Labò N; Whitby D J Immunol Methods; 2010 Apr; 356(1-2):39-46. PubMed ID: 20211626 [TBL] [Abstract][Full Text] [Related]
14. Human herpesvirus 8/Kaposi sarcoma herpesvirus cell association during evolution of Kaposi sarcoma. Pyakurel P; Massambu C; Castaños-Vélez E; Ericsson S; Kaaya E; Biberfeld P; Heiden T J Acquir Immune Defic Syndr; 2004 Jun; 36(2):678-83. PubMed ID: 15167286 [TBL] [Abstract][Full Text] [Related]
15. The effects of human herpesvirus 8 infection and interferon-gamma response in cutaneous lesions of Kaposi sarcoma differ among human immunodeficiency virus-infected and uninfected individuals. Guedes F; de Andrade HF; Fernandes ER; Tuon FF; Brasil RA; Pagliari C; Duarte MI Br J Dermatol; 2008 Sep; 159(4):839-46. PubMed ID: 18644020 [TBL] [Abstract][Full Text] [Related]
16. Kaposi's sarcoma-associated herpesvirus seroprevalence in selected german patients: evaluation by different test systems. Preiser W; Szép NI; Lang D; Doerr HW; Rabenau HF Med Microbiol Immunol; 2001 Dec; 190(3):121-7. PubMed ID: 11827200 [TBL] [Abstract][Full Text] [Related]
17. A common genetic variant in FCGR3A-V158F and risk of Kaposi sarcoma herpesvirus infection and classic Kaposi sarcoma. Brown EE; Fallin MD; Goedert JJ; Chen R; Whitby D; Foster CB; Lauria C; Alberg AJ; Messina A; Montella M; Rezza G; Vitale F; Chanock SJ; Cancer Epidemiol Biomarkers Prev; 2005 Mar; 14(3):633-7. PubMed ID: 15767342 [TBL] [Abstract][Full Text] [Related]
18. Identification, expression, and immunogenicity of Kaposi's sarcoma-associated herpesvirus-encoded small viral capsid antigen. Lin SF; Sun R; Heston L; Gradoville L; Shedd D; Haglund K; Rigsby M; Miller G J Virol; 1997 Apr; 71(4):3069-76. PubMed ID: 9060668 [TBL] [Abstract][Full Text] [Related]
19. Kaposi's sarcoma-associated herpesvirus-specific immune reconstitution and antiviral effect of combined HAART/chemotherapy in HIV clade C-infected individuals with Kaposi's sarcoma. Bihl F; Mosam A; Henry LN; Chisholm JV; Dollard S; Gumbi P; Cassol E; Page T; Mueller N; Kiepiela P; Martin JN; Coovadia HM; Scadden DT; Brander C AIDS; 2007 Jun; 21(10):1245-52. PubMed ID: 17545700 [TBL] [Abstract][Full Text] [Related]
20. Reduced levels of neutralizing antibodies to Kaposi sarcoma-associated herpesvirus in persons with a history of Kaposi sarcoma. Kimball LE; Casper C; Koelle DM; Morrow R; Corey L; Vieira J J Infect Dis; 2004 Jun; 189(11):2016-22. PubMed ID: 15143468 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]